Emmessar Biotech

What does Emmessar Biotech do?

Emmessar Biotech & Nutrition Ltd manufactures Super Specialty Fine Chemicals and operates in the Commodity Chemicals industry. As of March 2025, it reported net sales and profit of 0 Cr, with a market cap of Rs 17 Cr.

Overview:<BR>Emmessar Biotech & Nutrition Ltd is engaged in the manufacturing of Super Specialty Fine Chemicals and operates within the Commodity Chemicals industry, classified as a Micro Cap company.<BR><BR>History:<BR>The company was originally established on 17th March 1992 as Emmessar Chemical Industries Ltd (ECIL). It has developed numerous Specialty Fine Chemicals and received official recognition for its R&D from the DSIR, Ministry of Science & Technology, Government of India, in early 1996. The latest quarterly results reported net sales and net profit of 0 Cr for March 2025.<BR><BR>Financial Snapshot:<BR>- Net Sales: 0 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: 0 Cr (Quarterly Results - Mar 2025)<BR>- Market Cap: Rs 17 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 16.00<BR>- Industry P/E: 47<BR>- Dividend Yield: 0.00%<BR>- Debt-Equity: -0.89<BR>- Return on Equity: 4.15%<BR>- Price to Book: 2.12<BR><BR>Contact Details:<BR>- Address: Plot No T-3/2 MIDC Area, P O Box No 39 Taloja Raigad Maharashtra : 410208<BR>- Tel: 91-022-20870587<BR>- Email: investors@ebnl.co.in/emmessar@vsnl.<BR>- Website: http://www.ebnl.co.in

Has Emmessar Biotech declared dividend?

No Dividend History Available

Who are the peers of the Emmessar Biotech?

Emmessar Biotech's peers include Tata Chemicals, Chemplast Sanmar, GHCL, India Glycols, Fischer Medical, Link Pharma Chem, Vivid Global, Kuwer Industries, and Bhagawati Oxygen. In terms of management risk, GHCL and Chemplast Sanmar are rated excellent, while Emmessar Biotech has average risk; India Glycols leads in 1-year returns at 150.59%, while Emmessar Biotech has a return of -18.82%.

Peers: The peers of Emmessar Biotech are Tata Chemicals, Chemplast Sanmar, GHCL, India Glycols, Fischer Medical, Link Pharma Chem, Vivid Global, Kuwer Industries, and Bhagawati Oxygen.<BR><BR>Quality Snapshot: Excellent management risk is observed at GHCL and Chemplast Sanmar, while Average management risk is found at Tata Chemicals, India Glycols, Emmessar Biotech, Link Pharma Chem, and the rest. Below Average management risk is noted at Fischer Medical, Vivid Global, Kuwer Industries, and Bhagawati Oxygen. Growth is rated as Below Average for Tata Chemicals, Chemplast Sanmar, GHCL, India Glycols, Emmessar Biotech, Link Pharma Chem, and the rest, while Average growth is seen at Fischer Medical. Good growth is observed at Vivid Global and Kuwer Industries, while Bhagawati Oxygen does not qualify. Capital Structure is rated as Excellent for GHCL, Good for Fischer Medical, Average for Tata Chemicals, Chemplast Sanmar, Emmessar Biotech, Link Pharma Chem, and the rest, and Below Average for Vivid Global, Kuwer Industries, and Bhagawati Oxygen.<BR><BR>Return Snapshot: India Glycols has the highest 1-year return at 150.59%, while Emmessar Biotech has a 1-year return of -18.82%, which is lower than all peers except Chemplast Sanmar, Tata Chemicals, and Vivid Global. Additionally, the six-month return is negative for Tata Chemicals, Chemplast Sanmar, Emmessar Biotech, Vivid Global, Kuwer Industries, and Lime Chemicals.

Is Emmessar Biotech overvalued or undervalued?

As of April 25, 2023, Emmessar Biotech is rated as risky and overvalued, with a PE ratio of 16.32, a Price to Book Value of 2.12, a troubling ROCE of -104%, and has underperformed the Sensex by declining 26.44% year-to-date.

As of 25 April 2023, the valuation grade for Emmessar Biotech has moved from does not qualify to risky, indicating a heightened level of concern regarding its financial stability. The company is currently assessed as overvalued. Key ratios include a PE ratio of 16.32, a Price to Book Value of 2.12, and a troubling ROCE of -104.00%. <BR><BR>In comparison to its peers, Emmessar Biotech's PE ratio is significantly lower than that of Solar Industries, which stands at 123.77, and Godrej Industries at 46.63, both of which are considered very expensive. The negative EV to EBIT and EV to EBITDA ratios of -9.07 and -9.44, respectively, further highlight the company's financial challenges. Notably, Emmessar's stock has underperformed relative to the Sensex, particularly year-to-date, where it has declined by 26.44% compared to the Sensex's gain of 5.61%.

What is the technical trend for Emmessar Biotech?

As of May 30, 2025, Emmessar Biotech's technical trend is mildly bearish, influenced by bearish moving averages and Bollinger Bands, despite some mildly bullish signals from the weekly MACD and KST.

As of 30 May 2025, the technical trend for Emmessar Biotech has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD is mildly bearish. The Bollinger Bands are bearish on both weekly and monthly time frames. Daily moving averages are bearish, and the KST shows a mildly bullish signal weekly but mildly bearish monthly. Dow Theory reflects a mildly bearish trend weekly, contrasting with a mildly bullish stance monthly. Overall, the current technical stance is mildly bearish, driven primarily by the bearish moving averages and Bollinger Bands, despite some mildly bullish indicators on the weekly MACD and KST.

Who are in the management team of Emmessar Biotech?

As of March 2023, the management team of Emmessar Biotech includes MSR Ayyangar (Chairman & Managing Director), Anuradha Raghavan, Sarada Raghavan, Rajalakshmi Srinivasa Raghavan (Non Executive Directors), Anantharama Sethmani Subramanian, Milind S Desai (Independent Directors), Jayavel Balaiah Nadar (Executive Director & CFO), and Priyanka Omprakash Sharma (Company Secretary & Compliance Officer). Each member contributes to the company's governance and management.

As of March 2023, the management team of Emmessar Biotech includes the following individuals:<BR><BR>1. MSR Ayyangar - Chairman & Managing Director<BR>2. Anuradha Raghavan - Non Executive Director<BR>3. Sarada Raghavan - Non Executive Director<BR>4. Anantharama Sethmani Subramanian - Independent Director<BR>5. Jayavel Balaiah Nadar - Executive Director & CFO<BR>6. Rajalakshmi Srinivasa Raghavan - Non Executive Director<BR>7. Priyanka Omprakash Sharma - Company Secretary & Compliance Officer<BR>8. Milind S Desai - Independent Director<BR><BR>Each member plays a distinct role in the governance and management of the company.

Who are the top shareholders of the Emmessar Biotech?

The top shareholders of Emmessar Biotech include Emmessar Technologies Limited with 21.79%, individual investors with 37.15%, and Sandeep Rao as the highest public shareholder at 2.04%. There are no foreign institutional investors, and no promoter holdings are pledged.

The top shareholders of Emmessar Biotech include the promoters, with Emmessar Technologies Limited holding the largest stake at 21.79%. Additionally, individual investors collectively own 37.15% of the company. The highest public shareholder is Sandeep Rao, who holds 2.04%. There are also two mutual fund schemes that hold a very small percentage of shares (0.05%), and currently, there are no foreign institutional investors (FIIs) involved. Notably, there are no pledged promoter holdings.

How big is Emmessar Biotech?

As of 24th July, Emmessar Biotech & Nutrition Ltd has a market capitalization of 16.00 Cr, with recent net sales of 0.62 Cr and a net profit of 0.32 Cr. Shareholder's funds are 7.40 Cr, and total assets amount to 8.74 Cr.

As of 24th July, Emmessar Biotech & Nutrition Ltd has a market capitalization of 16.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 0.62 Cr and a Net Profit of 0.32 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024, with Shareholder's Funds amounting to 7.40 Cr and Total Assets of 8.74 Cr.

How has been the historical performance of Emmessar Biotech?

Emmessar Biotech has experienced significant fluctuations in financial performance, with net sales and operating income peaking at 6.99 Cr in Mar'21 before declining to 0.61 Cr in Mar'25, while operating profit turned negative and total assets and liabilities increased. The company has shown a consistent zero balance in cash and cash equivalents, indicating poor cash flow.

Answer:<BR>The historical performance of Emmessar Biotech shows significant fluctuations in its financial metrics over the years.<BR><BR>Breakdown:<BR>Emmessar Biotech's net sales have varied considerably, peaking at 6.99 Cr in Mar'21 before declining to 0.61 Cr in Mar'25. The total operating income followed a similar trend, with a high of 6.99 Cr in Mar'21 and a drop to 0.61 Cr in Mar'25. The company's total expenditure, excluding depreciation, has also seen fluctuations, reaching a high of 6.14 Cr in Mar'21 and decreasing to 1.56 Cr in Mar'25. Operating profit (PBDIT) has been negative in recent years, with a loss of 0.95 Cr in Mar'25, contrasting with a profit of 0.85 Cr in Mar'21. Profit after tax has decreased from 1.45 Cr in Mar'21 to 0.32 Cr in Mar'25. The company's total assets have increased from 5.19 Cr in Mar'20 to 9.22 Cr in Mar'25, while total liabilities have also risen from 5.19 Cr to 9.22 Cr in the same period. Cash and cash equivalents have shown a consistent zero balance from Mar'20 to Mar'25, indicating a lack of cash flow from operations. Overall, Emmessar Biotech has experienced a decline in sales and profitability, alongside an increase in total assets and liabilities.

Which are the latest news on Emmessar Biotech?

When is the next results date for Emmessar Biotech & Nutrition Ltd?

The next results date for Emmessar Biotech & Nutrition Ltd is 12 May 2026.

The next results date for Emmessar Biotech & Nutrition Ltd is scheduled for 12 May 2026.

Why is Emmessar Biotech & Nutrition Ltd falling/rising?

As of 06-May, Emmessar Biotech & Nutrition Ltd's stock is at 25.30, down 2.39%, and has underperformed the sector by 4.73%. It is trading below all major moving averages and has declined 13.80% year-to-date, significantly worse than the Sensex's 8.52% drop.

As of 06-May, Emmessar Biotech & Nutrition Ltd's stock price is falling, currently at 25.30, which reflects a decrease of 0.62 or 2.39%. The stock has underperformed compared to the sector today by 4.73%. Additionally, it is trading lower than its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a downward trend in its price performance. <BR><BR>In the context of recent performance, the stock has seen a decline of 1.82% over the past week, while the benchmark Sensex has increased by 0.60%. Year-to-date, the stock is down 13.80%, compared to a smaller decline of 8.52% for the Sensex. Over the past year, Emmessar Biotech has dropped 26.65%, significantly underperforming the Sensex, which has only decreased by 3.33%. <BR><BR>Despite a rise in delivery volume by 19.69% against the 5-day average, which indicates increased investor participation, the overall performance metrics suggest that the stock is struggling to gain traction in the market.